Pipeline Insight: Asthma/COPD - Targeted therapies on the horizon

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-11-07

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The total asthma and COPD population in 2006 is estimated to be 44.8 million and 28.8 million respectively. While the majority of patients are well controlled with current therapies, the remaining unmet needs are twofold: first, to find better options for the 1.7 million patients with severe asthma; second, to identify effective anti-inflammatory drugs in COPD.


Scope

  • Discussion and quantification of the patient potential and segmentation in both Asthma and COPD
  • Detailed overview and assessment of drugs in mid-to late stage clinical development, highlighting recent clinical trial results
  • Assessment of the remaining unmet clinical needs in both asthma and COPD, analyzing the potential of new targeted therapies
  • Ten year indication-based sales forecast to 2015 for major Phase III to recently launched drugs


    • Report Highlights
    Global asthma/COPD sales are forecast to grow to $30 billion by 2015, with ICS/LABA combinations set to retain their leading position by value, followed by anticholinergics. The ICS/LABA class was long dominated by GlaxoSmithKline's Advair/Seretide but will see dramatically increased competition in the future with several new product launches.

    Despite many years and billions of dollars spent on finding drugs that slow or reverse disease progression in COPD, progress remains elusive. Several drugs that were initially hailed as breakthroughs have failed to live up to their initial promise, but conservative drug regulators and badly chosen clinical endpoints may have to share the blame.

    Targeted therapies offer new hope for severe asthma sufferers. Despite several setbacks over the past years, the research pipeline remains full. Although it is still difficult to predict which approach may work for whom, Amgen/Wyeth's anti-TNF alpha therapy Enbrel is thought to be the next biological drug to be launched in asthma.


    Reasons to Purchase

  • Identify the remaining opportunities in the Asthma and COPD market place and possible licensing partners
  • Learn about new biological targeted therapy approaches, shifting R&D approaches and changing clinical trial endpoints
  • Evaluate forecasts of the asthma/COPD market to 2015, and predict the performance of key drugs

    • Table of Contents

    Other users found this report page using the following search terms: asthma copd emphysema respiratory bronchitis airway copd lama smile asthma trial indacaterol mometasone icslaba therapies boehringer

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.